Manager × security

Avoro Capital Advisors LLC ARWR holdings history

Who else holds this security? →

ARROWHEAD PHARMACEUTICALS IN · CUSIP 04280A100 · CIK 1633313

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Avoro Capital Advisors LLC reported 11.36M ARWR (shares), valued at $925.59M, or 8.31% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
8.31%
Shares
11.36M
11,355,555
Reported value
$925.59M
USD

Shares increased 6.13%; reported value increased 37.96%, and weight changed +1.70 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20268.31%11,355,555SEC filing ↗Filed Aug 14, 2026
Q1 20266.61%10,699,999SEC filing ↗Filed May 15, 2026
Q4 20256.93%10,625,000SEC filing ↗Filed Mar 16, 2026Amended
Q3 20254.86%10,900,000SEC filing ↗Filed Nov 14, 2025
Q2 20252.93%10,600,000SEC filing ↗Filed Aug 14, 2025
Q1 20252.21%11,111,111SEC filing ↗Filed May 15, 2025
Q4 20242.95%11,111,111SEC filing ↗Filed Feb 14, 2025
Q3 20242.51%8,888,888SEC filing ↗Filed Nov 14, 2024
Q2 20243.08%8,888,888SEC filing ↗Filed Aug 14, 2024
Q1 20242.85%8,555,555SEC filing ↗Filed May 15, 2024
Q4 20230.48%1,130,000SEC filing ↗Filed Feb 14, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20230.48%1,130,000$34.58MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Feb 14, 2024
Q1 20242.85%8,555,555$244.69MShares increased 657.13%; reported value increased 607.64%, and weight changed +2.37 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20243.08%8,888,888$231.02MShares increased 3.90%; reported value decreased 5.59%, and weight changed +0.23 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20242.51%8,888,888$172.18MShares unchanged; reported value decreased 25.47%, and weight changed -0.57 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20242.95%11,111,111$208.89MShares increased 25.00%; reported value increased 21.32%, and weight changed +0.44 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20252.21%11,111,111$141.56MShares unchanged; reported value decreased 32.23%, and weight changed -0.74 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20252.93%10,600,000$167.48MShares decreased 4.60%; reported value increased 18.31%, and weight changed +0.72 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20254.86%10,900,000$375.94MShares increased 2.83%; reported value increased 124.47%, and weight changed +1.93 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20256.93%10,625,000$705.39MShares decreased 2.52%; reported value increased 87.63%, and weight changed +2.07 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Mar 16, 2026
Q1 20266.61%10,699,999$670.89MShares increased 0.71%; reported value decreased 4.89%, and weight changed -0.32 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20268.31%11,355,555$925.59MShares increased 6.13%; reported value increased 37.96%, and weight changed +1.70 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
Avoro Capital Advisors LLC · ARROWHEAD PHARMACEUTICALS IN

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1633313","quarter":"2026Q2","cusip":"04280A100"}

get_institutional_manager_history
{"cik":"1633313","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.